{"id":943007,"date":"2026-03-09T16:18:16","date_gmt":"2026-03-09T20:18:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/"},"modified":"2026-03-09T16:18:16","modified_gmt":"2026-03-09T20:18:16","slug":"precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/","title":{"rendered":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026"},"content":{"rendered":"

<\/p>\n

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026<\/b><\/p>\n

DURHAM, N.C.–(BUSINESS WIRE<\/a>)–
\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo<\/i> gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026.<\/p>\n

About Precision BioSciences, Inc.<\/b><\/p>\n

\nPrecision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae<\/sup> genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases to drive more defined therapeutic outcomes. Using ARCUS, the Company\u2019s pipeline is comprised of clinical stage in vivo<\/i> gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com<\/b><\/a>.<\/p>\n

\nThe ARCUS\u00ae<\/sup> platform is being used to develop in vivo<\/i> gene editing therapies for sophisticated gene edits, including, elimination (removing a genome e.g. viral DNA such as in the Company\u2019s PBGENE-HBV program), excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the Company\u2019s DMD program) and gene insertion (inserting DNA into gene to cause expression\/add function).<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260309157101\/en\/<\/a><\/span><\/p>\n

Investor and Media Contact:
\n<\/b>
Naresh Tanna
\n
Vice President of Investor Relations
\n
naresh.tanna@precisionbiosciences.com<\/a><\/p>\n

KEYWORDS:<\/b> North Carolina United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Other Health Research General Health Infectious Diseases Genetics Clinical Trials Science Biotechnology Stem Cells FDA Other Science Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 DURHAM, N.C.–(BUSINESS WIRE)– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended … <\/p>\n

Continue reading “Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943007","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 DURHAM, N.C.–(BUSINESS WIRE)– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended … Continue reading "Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T20:18:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026\",\"datePublished\":\"2026-03-09T20:18:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/\"},\"wordCount\":314,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/\",\"name\":\"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-03-09T20:18:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/","og_locale":"en_US","og_type":"article","og_title":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Market Newsdesk","og_description":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 DURHAM, N.C.–(BUSINESS WIRE)– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended … Continue reading \"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-09T20:18:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026","datePublished":"2026-03-09T20:18:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/"},"wordCount":314,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/","name":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-03-09T20:18:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260309157101r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/precision-biosciences-to-report-fourth-quarter-and-fiscal-year-2025-results-on-march-12-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943007"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943007\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}